S Emery

Summary

Affiliation: University of New South Wales
Country: Australia

Publications

  1. ncbi request reprint Immune reconstitution in HIV infection
    S Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 2nd Floor, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    Curr Opin Immunol 9:568-72. 1997
  2. ncbi request reprint Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
    S Emery
    National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW 2010, Australia
    J Infect Dis 182:428-34. 2000
  3. ncbi request reprint Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
  4. ncbi request reprint HIV medicine
    Sean Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010
    Med J Aust 176:21. 2002
  5. ncbi request reprint The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT
    Sean Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
    Control Clin Trials 23:198-220. 2002
  6. ncbi request reprint Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy
    S Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Hum Vaccin 3:260-7. 2007
  7. ncbi request reprint Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2
    J Amin
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
    HIV Clin Trials 4:252-61. 2003
  8. ncbi request reprint Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy
    H Byakwaga
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
    HIV Med 10:143-51. 2009
  9. ncbi request reprint Immunomodulators as adjunctive therapy for HIV-1 infection
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
    J Clin Virol 22:289-95. 2001
  10. ncbi request reprint A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study
    A Carr
    HIV, Immunology and Infectious Disease Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    AIDS 14:1171-80. 2000

Detail Information

Publications66

  1. ncbi request reprint Immune reconstitution in HIV infection
    S Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 2nd Floor, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    Curr Opin Immunol 9:568-72. 1997
    ..These observations have implications for clinical management, therapeutic strategies, and future research...
  2. ncbi request reprint Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
    S Emery
    National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW 2010, Australia
    J Infect Dis 182:428-34. 2000
    ..98 vs. -0.63 log copies/mL; P=.004). Significant improvements in CD4 cell count and plasma HIV RNA in recipients of IL-2 relative to control patients were associated with a nonsignificant trend toward improved clinical outcome...
  3. ncbi request reprint Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
    ..In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART...
  4. ncbi request reprint HIV medicine
    Sean Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010
    Med J Aust 176:21. 2002
  5. ncbi request reprint The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT
    Sean Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
    Control Clin Trials 23:198-220. 2002
    ..This article describes the rationale supporting the trial in addition to reviewing the study design, coordination, and governance...
  6. ncbi request reprint Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy
    S Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Hum Vaccin 3:260-7. 2007
    ..The promising antiretrovirological effect supports further study of FC in a larger trial with a broader population of patients with HIV disease...
  7. ncbi request reprint Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2
    J Amin
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
    HIV Clin Trials 4:252-61. 2003
    ..To compare inhibition of HIV replication, improvements in CD4+ T-cell counts, metabolic parameters, and body shape changes after 2 years of assigned therapy in OzCombo patients...
  8. ncbi request reprint Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy
    H Byakwaga
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
    HIV Med 10:143-51. 2009
    ..The aim of the study was to determine the effect of nucleoside reverse transcriptase inhibitors (NRTIs) on CD4 recovery in HIV-1-infected individuals receiving long-term suppressive combination antiretroviral therapy (cART)...
  9. ncbi request reprint Immunomodulators as adjunctive therapy for HIV-1 infection
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
    J Clin Virol 22:289-95. 2001
    ..However, the immunological competency and therefore clinical impact of this expanded CD4(+) T cell pool is yet to be established; this question is the focus of two large clinical end-point studies, ESPRIT and SILCAAT...
  10. ncbi request reprint A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study
    A Carr
    HIV, Immunology and Infectious Disease Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    AIDS 14:1171-80. 2000
    ..The best-tolerated and most potent initial HAART regimen is unknown and was investigated in this study...
  11. ncbi request reprint Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up
    D Carey
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW, Australia
    HIV Med 10:163-72. 2009
    ..Poly-l-lactic acid (PLA) injections modestly increase objectively assessed facial thickness but not facial soft tissue volume (FSTV) over 24 weeks. The durability of this response has not been well defined objectively...
  12. pmc Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database
    H Byakwaga
    The Kirby Institute, University of New South Wales, Sydney, Australia
    J Int Assoc Provid AIDS Care 12:270-7. 2013
    ..In conclusion, measurements of CD4 count and hemoglobin at month 6 may be useful for early identification of disease progression in resource-limited settings. ..
  13. ncbi request reprint Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group
    A Carr
    HIV Medicine Unit, St Vincent s Hospital, Sydney, Australia
    J Infect Dis 178:992-9. 1998
    ..HIV RNA levels were unaffected. IL-2 therapy may expand the existing immune repertoire but not immediately reconstitute lost immune function...
  14. ncbi request reprint Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, 2010, Australia
    J Antimicrob Chemother 56:380-7. 2005
    ..The aim of this study was to assess the clinical associations with plasma atazanavir concentrations in HIV-positive individuals...
  15. ncbi request reprint Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy
    A Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Med 7:105-11. 2006
    ..The aim of this study was to assess changes in renal parameters in individuals receiving TDF- and non-TDF-containing highly active antiretroviral therapy (HAART)...
  16. ncbi request reprint Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research UNSW, 5St Vincent s Centre for Applied Medical Research, Sydney, Australia
    Clin Infect Dis 49:1591-601. 2009
    ..Which fixed-dose-combination tablet is more effective and safe is uncertain...
  17. ncbi request reprint The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 44:1475-83. 2007
    ..Ritonavir-boosted double-protease inhibitor (PI)-only regimens are such an option but are prone to pharmacokinetic interactions...
  18. ncbi request reprint The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals
    Alan Winston
    National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
    AIDS 19:1393-9. 2005
    ..We undertook an assessment of NIQ and 48-week virological outcome in patients commencing ritonavir-boosted protease inhibitor (PI) regimens...
  19. ncbi request reprint Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study
    Allison Martin
    National Centree in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 18:1029-36. 2004
    ..To determine if long-term improvement in HIV lipoatrophy can be attained by substitution of thymidine analogues zidovudine (ZDV) or stavudine (d4T) with abacavir (ABC)...
  20. doi request reprint Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    J Infect Dis 198:1794-803. 2008
    ..Rosiglitazone (RSG), a PPARgamma agonist, improves congenital lipoatrophy but not HIV lipoatrophy...
  21. ncbi request reprint Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia
    AIDS Res Hum Retroviruses 22:338-41. 2006
    ..In this cohort of highly treatment-experienced individuals treated with NNRTI regimens, we did not observe a significant association between NNRTI plasma concentration and virological response...
  22. ncbi request reprint Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects
    S Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Hum Vaccin 1:232-8. 2005
    ..Although safe, neither vaccine construct appeared to possess detectable T-cell mediated anti-HIV immunogenic properties in HIV infected individuals, as measured by standard T cell assays...
  23. doi request reprint Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy
    A Calmy
    St Vincent s Hospital, Sydney, Australia
    HIV Med 9:101-10. 2008
    ..We investigated whether metabolic and body composition parameters could predict the development of LD over 2 years in adults initiating antiretroviral therapy (ART)...
  24. ncbi request reprint No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
    Andrew Carr
    St Vincent s Hospital, Sydney, Australia
    Lancet 363:429-38. 2004
    ..We postulated that rosiglitazone would improve HIV lipoatrophy...
  25. ncbi request reprint Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection
    Handan Wand
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    AIDS 21:2445-53. 2007
    ..Metabolic syndrome (MS) identifies individuals at risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Little is known about MS and its consequences following initiation of antiretroviral therapy (ART)...
  26. ncbi request reprint HIV lipodystrophy: prevalence, severity and correlates of risk in Australia
    J Miller
    The National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Med 4:293-301. 2003
    ..To establish the prevalence, severity and factors associated with the HIV lipodystrophy syndrome...
  27. ncbi request reprint A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    AIDS Res Hum Retroviruses 26:653-61. 2010
    ..The persistence and clinical meaning of these immunological changes during long-term exposure to this class of anti-HIV drugs are unknown, but may have implications for immunosurveillance of inflammation...
  28. ncbi request reprint Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
    John M Murray
    National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW 2052, Australia
    AIDS 21:2315-21. 2007
    ..To date, there have been no reports investigating the potential for differential effects on viral dynamics with integrase inhibitors relative to current antiretroviral drugs...
  29. ncbi request reprint Role of interleukin-2 in patients with HIV infection
    Sarah L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    Drugs 70:1115-30. 2010
    ..Moreover, there was an excess of grade 4 clinical events in ESPRIT rIL-2 recipients. The results of the phase III clinical endpoint studies showed that rIL-2 has no place as a therapeutic agent in the treatment of HIV infection...
  30. doi request reprint Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    AIDS 24:2657-63. 2010
    ..7, P = 0.048) in ABC/3TC recipients compared with TDF/FTC in the STEAL study. The impact of ABC/3TC treatment on a range of CVD and inflammatory biomarkers was explored...
  31. ncbi request reprint A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy
    Dianne L Carey
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 46:581-9. 2007
    ..Facial lipoatrophy can stigmatize and can reduce quality of life, self esteem, and antiretroviral adherence. Poly-L-lactic acid (PLA) injections seem safe and effective, but no randomized study has included objective endpoints...
  32. ncbi request reprint Restorative interventions for HIV facial lipoatrophy
    Dianne Carey
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS Rev 10:116-24. 2008
    ..However, well-designed studies with objectively assessed endpoints are needed to elucidate optimal treatments for this distressing condition...
  33. ncbi request reprint Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study
    Rebekah L Puls
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, 45 Beach St, Coogee, New South Wales, Australia, 2034
    Clin Infect Dis 51:855-64. 2010
    ..Antiretroviral therapy is complicated by drug interactions and contraindications. Novel regimens are needed...
  34. doi request reprint Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression
    Helen Byakwaga
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
    AIDS Res Hum Retroviruses 25:756-76. 2009
    ..Our results point to an advantage to commencing ART at higher CD4+ T cell strata. These data should be considered when estimating the optimal time to initiate ART...
  35. doi request reprint High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)
    John J Zaunders
    Centre for Immunology, St Vincent s Hospital, Sydney, New South Wales, Australia
    J Immunol 183:2827-36. 2009
    ..In addition to revealing the true extent of Ag-specific human CD4(+) memory T lymphocytes, its greatest use will be as a simple in vitro monitor of CD4(+) T cell responses to Ags such as tuberculosis infection or vaccines...
  36. ncbi request reprint Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials
    Dianne Carey
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney 2052, New South Wales, Australia
    J Antimicrob Chemother 65:1878-88. 2010
    ..To compare lipid profiles in HIV-infected adults receiving atazanavir-based regimens...
  37. ncbi request reprint A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 14:111-5. 2009
    ..SCH532706 is a novel small molecule chemokine receptor-5 (CCRS) antagonist with high in vitro potency (mean 90% inhibitory concentration [IC90] 0.15-7.0 nM) against diverse HIV type-1 (HIV-1) isolates...
  38. pmc Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients
    Amit C Achhra
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Cliffbrook Campus, Coogee, Sydney, New South Wales, Australia
    AIDS 24:1877-86. 2010
    ..To investigate the relative predictive value of CD4(+) metrics for serious clinical endpoints...
  39. ncbi request reprint Antivirals in the management of an influenza pandemic
    Mary Ellen Harrod
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
    Med J Aust 185:S58-61. 2006
    ..The safety and efficacy (including resistance) of neuraminidase inhibitors against pandemic influenza or the virus of current concern in pandemic planning, influenza A/H5N1, is not known, and further research is needed...
  40. ncbi request reprint In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia
    J Infect Dis 191:1686-96. 2005
    ..The effects of this mitochondrial dysfunction on lipid metabolism, at a molecular level in vivo, have not been described...
  41. ncbi request reprint Therapeutic vaccination against HIV: current progress and future possibilities
    Rebekah L Puls
    National Centre in HIV Epidemiology and Clinical Research NCHECR, University of New South Wales UNSW, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    Clin Sci (Lond) 110:59-71. 2006
    ....
  42. ncbi request reprint A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services, St Vincent s Hospital, Sydney, and National Centre in HIV Epidemiology and Clinical Research, University of NSW, Darlinghurst, Sydney, Australia
    HIV Clin Trials 5:91-8. 2004
    ..To establish the pharmacokinetics and safety of single-dose polyclonal caprine anti-HIV antibodies ((PE)HRG214)in HIV-1-infected individuals...
  43. doi request reprint Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 25:1727-35. 2011
    ..To examine HIV and hepatitis B virus (HBV)-related outcomes in HIV/HBV-coinfected participants in the PHIDISA II study by use of HBV-active vs. non-HBV-active antiretroviral therapy (ART)...
  44. pmc Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Med 12:219-27. 2011
    ..cART alone (control arm) in HIV-infected adults with CD4 counts ≥300cells/μL, offered the opportunity to explore associations between bacterial pneumonia and rIL-2, a cytokine that increases the risk of some bacterial infections...
  45. ncbi request reprint Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism
    Katherine Samaras
    Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW 2010, Australia
    Curr HIV Res 7:454-61. 2009
    ..Only interventional, prospective studies will determine whether any nutritional strategy can assist in ameliorating the metabolic complications associated with HIV lipodystrophy...
  46. ncbi request reprint Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy
    Jason C Kovacic
    Cardiology Department, HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 10:135-43. 2005
    ..This study sought to investigate the effects of rosiglitazone on endothelial function and other markers of cardiovascular risk in patients with HIV-related lipoatrophy...
  47. ncbi request reprint Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial
    Dianne Carey
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    AIDS 19:1325-7. 2005
    ..Changes in facial fat assessed by ultrasonography did not correlate significantly with more established objective measures of lipoatrophy severity. The measurement of malar fat using ultrasonography is not recommended...
  48. ncbi request reprint Selective exclusion of treatment arms in multi-arm randomized clinical trials
    Matthew G Law
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
    Stat Med 22:19-30. 2003
    ..However, the duration of time taken to recruit the study would be reduced. The implications for the design, monitoring and analysis of such RCTs are discussed...
  49. ncbi request reprint Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmental
    Katherine Samaras
    Diabetes and Obesity Programme, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia
    Diabetes Care 30:113-9. 2007
    ..The purpose of this study was to report the prevalence of metabolic syndrome in HIV-infected patients and compare insulin resistance and total body, limb, and visceral fat and adipokines in those with and without metabolic syndrome...
  50. ncbi request reprint An objective case definition of lipodystrophy in HIV-infected adults: a case-control study
    A Carr
    HIV, Immunology, and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Lancet 361:726-35. 2003
    ..However, an objective, validated definition of the disorder does not exist. We aimed to develop an objective, sensitive, specific, and broadly applicable case definition of HIV lipodystrophy...
  51. ncbi request reprint Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study
    Martyn French
    Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, WA, Australia
    HIV Clin Trials 3:177-85. 2002
    ..To assess and compare the efficacy and safety of three triple combination antiretroviral therapies in HIV-1-infected treatment-naive patients...
  52. ncbi request reprint CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies
    Roberto C Arduino
    The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Clin Infect Dis 39:115-22. 2004
    ..To more precisely quantitate the effect on CD4 cell response of 3 different doses of scIL-2 that were administered twice daily for 5 days every 8 weeks, the results of these 3 trials were pooled in a meta-analysis...
  53. ncbi request reprint Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection
    Chaiwat Ungsedhapand
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 36:693-701. 2004
    ..Triple-nucleoside therapy with ZDV, 3TC, and ddI or d4T, 3TC, and ABC in patients with HIV infection is more effective in inducing a sustained virologic response than the dual combinations of ZDV and 3TC or ddI and d4T...
  54. ncbi request reprint The development of artificial neural networks to predict virological response to combination HIV therapy
    Brendan Larder
    The HIV Resistance Response Database Initiative, London, UK
    Antivir Ther 12:15-24. 2007
    ..The choice of an alternative regimen may be guided by a drug-resistance test. However, interpretation of resistance from genotypic data poses a major challenge...
  55. ncbi request reprint Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors
    Sunee Sirivichayakul
    Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    AIDS 17:1889-96. 2003
    ..To investigate genotypic drug resistance in HIV-1 subtype A/E infection associated with failure of double/triple-nucleoside reverse transcriptase (RT) inhibitor therapy...
  56. ncbi request reprint Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data
    Bart Winters
    Virco BVBA, Mechelen, Belgium
    J Acquir Immune Defic Syndr 48:26-34. 2008
    ..Clinically relevant cutoffs are needed for the interpretation of HIV-1 phenotypic resistance estimates as predicted by "virtual" phenotype HIV resistance analysis...
  57. doi request reprint Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatment
    David A Cooper
    J Infect Dis 197:775; author reply 775-6. 2008
  58. ncbi request reprint HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting
    Chris Duncombe
    HIV Netherlands Australia Thailand Research Collaboration, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    AIDS 19:169-78. 2005
    ..DESIGN, SETTING, PARTICIPANTS AND INTERVENTION: A cohort of 417 patients enrolled in a series of randomized ART trials, between 1996 and December 2002...
  59. ncbi request reprint Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
    ..Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported...
  60. ncbi request reprint Chemokine receptor genotype and response to interleukin-2 therapy in HIV-1-infected individuals
    Alison Clegg
    Department of Immunology, Westmead Hospital, New South Wales 2145, Australia
    Clin Immunol 106:36-40. 2003
    ..03). This study highlights the importance of interactions between IL-2 and CCR5; at the clinical level, it argues for assessment of chemokine receptor genotype in IL-2 and perhaps other immune-based therapy trials...
  61. ncbi request reprint Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing
    Chris Birch
    Victorian Infectioud Diseases Reference Laboratory, North Melbourne, Australia
    J Acquir Immune Defic Syndr 32:57-61. 2003
    ..02), however. In general, our results suggest that patients should continue current therapy until test results are available. A few patients would be expected to gain ARV drug-associated resistance mutations during this time, however...
  62. pmc Determination of the underlying cause of death in three multicenter international HIV clinical trials
    Alan R Lifson
    University of Minnesota, Minneapolis, Minnesota 55454 1015, USA
    HIV Clin Trials 9:177-85. 2008
    ..Describe processes and challenges for an Endpoint Review Committee (ERC) in determining and adjudicating underlying causes of death in HIV clinical trials...
  63. ncbi request reprint Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting
    Somsamorn Mangclaviraj
    Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Int J STD AIDS 19:529-32. 2008
    ..In settings where access to affordable treatment is improving, this study reinforces the importance of regular Pap smear screening in HIV-positive women, particularly those with low nadir CD4 counts and lower incomes...
  64. ncbi request reprint Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12
    C Jane Dale
    Department of Microbiology and Immunology, University of Melbourne, Royal Parade, VIC 3010, Australia
    Vaccine 23:188-97. 2004
    ..Non-sterilising protection from a non-pathogenic HIV-1 challenge was observed. This study provides evidence of a safe, optimised, strategy for the generation of T-cell mediated immunity to HIV-1...
  65. ncbi request reprint A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1
    Anthony D Kelleher
    AIDS 20:294-7. 2006
    ..The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9...